

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vigginia 22313-1450 www.uspto.gov

APPLICATION NO.		ING DATE	FIRST NAMED INVENTOR  Christian Behl	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/810,152	9/810,152 03/16/2001			MPG-10	2299
1473	7590	08/22/2003			
FISH & NEAVE				EXAMINER	
1251 AVENUE OF THE AMERICAS 50TH FLOOR			•	HUI, SAN MING R	
NEW YORK, NY 10020-110		20-1105	N <sub>1</sub>	ART UNIT	PAPER NUMBER
				1617 DATE MAILED: 08/22/2003	1%

Please find below and/or attached an Office communication concerning this application or proceeding.



## **Advisory Action**

Application No.	Applicant(s)		
09/810,152	BEHL ET AL.		
Examiner	Art Unit		
San-ming Hui	1617		

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 28 July 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

r. lı
ion sion or
е
t
ځ'
i di di

U.S. Patent and Trademark Office PTOL-303 (Rev. 04-01)

**Advisory Action** 

Part of Paper No. 16

Application No. 009/810,152

Continuation of 2. NOTE: The scope of the instant claims has changed. The proposed americaments delete lecithin, a second therapeutic agent taught by the prior art. Such amendments would necessitate a new search and a new ground of rejection. Therefore, the proposed americaments will not be entered.

Continuation of 5. does NOT place the application in condition for allowance because: As for the arguments with regards to rejection under 35 USC 102(b), Kathawala et al. teaches a tryptophanyl ester when R1 is C8. Examiner notes that claim 29 merely recite tryptophanyl ester, which reads on N-acyl tryptophanyl ester. As for the arguments with regards to the rejection under 35 USC 103, since the proposed amendments will not be entered, the arguments set forth in the previous office action will be still applicable. Exainer notes that the response are drawn to the claims in the proposed amendments.